Want to see BCAX full AI Analyst Report?
BCAX Stock Chart & Stats
$27.02
$0.79(2.92%)
At close: 4:00 PM EDT
$27.02
$0.79(2.92%)
Day’s Range― - ―
52-Week Range$10.30 - $30.99
Previous Close$27.81
Volume499.45K
Average Volume (3M)829.98K
Market Cap
$1.58B
Enterprise Value$1.52K
Total Cash (Recent Filing)$497.26M
Total Debt (Recent Filing)$1.16M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 17, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding66,172,935
10 Day Avg. Volume408,617
30 Day Avg. Volume829,976
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.29
Price to Sales (P/S)0.00
P/FCF Ratio-8.59
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.33Price Target Upside23.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Clinical EfficacyMulti-year follow-up showing durable survival, deep responses and consistent tolerability strengthens Ficera’s clinical differentiation. If replicated in Phase III, this profile could support regulatory approval and a durable position in recurrent or metastatic head and neck cancer.
Phase III Progress And Funded RunwayClear enrollment and interim-analysis milestones provide a defined path toward a registration decision, while cash funding into H1 2029 reduces near-term financing dependence. This supports continued investment in pivotal trials, manufacturing and launch preparation.
Strong Low-debt Balance SheetExtremely low leverage gives Bicara financial flexibility while it funds expensive clinical development. The substantial equity and asset base can absorb continued R&D investment more effectively than a highly indebted structure, lowering balance-sheet risk before commercialization.
Bears Say
Pre-revenue And Widening LossesBicara has no product revenue to offset its expanding development cost base, leaving the investment case dependent on clinical and regulatory success. Continued losses could persist for several years and increase the capital required to reach sustainable commercial profitability.
Heavy Negative Cash FlowDeep operating and free-cash-flow deficits show that Bicara converts funding into ongoing cash consumption rather than internally generated resources. Planned trial, manufacturing and commercial investments may sustain high burn, creating funding risk if timelines extend or results disappoint.
Competitive And Regulatory Execution RiskRival EGFR programs could affect treatment sequencing, enrollment and future commercial differentiation. In parallel, the alternative dosing regimen is not a non-inferiority study and its labeling is uncertain, creating lasting approval and adoption risks even if the pivotal program succeeds.
Bicara Therapeutics Inc. News
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $10.29 and its highest was $30.99 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $1.58B.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 85 days.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Aug 11, 2026. The company reported -$0.82 earnings per share for the quarter, the consensus estimate of -$0.82 by $0.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate is -0.81.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 66,172,935 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$0.82 in its last earnings report, expectations of -$0.82. Following the earnings report the stock price went down -14.317%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicara Therapeutics Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.33 (23.37% Upside)
$33.33 (23.37% Upside)
Blogger Sentiment
Bullish
BCAX Sentiment 100%
Sector Average 58%
Sector Average 58%
Hedge Fund Trend
Decreased
By 570.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 23.3%
Last 30 Days ▲ 23.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.93%
Trailing 12-Months
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
BCAX Company Deck
BCAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: mature 3-year efficacy and safety data for Ficera (≈33% 3-year survival, ~2x SOC), clear milestones (interim OS analysis mid-2027), initiation of an alternative dosing study timed for potential approval, and a planned leadership succession to support commercialization. These positives are balanced against rising operating expenses and planned commercialization spend, competitive timing uncertainty from other EGFR-directed agents, and small early CRC cohorts that will require further validation. Overall, the highlights—particularly the robust long-term efficacy signal, funded runway into H1 2029, and deliberate commercialization preparations—outweigh the near-term execution and competitive risks.View all BCAX earnings summariesBCAX Stock 12 Month Forecast
Average Price Target
$33.33
▲(23.37% Upside)
Technical Analysis
Sarepta Therapeutics
―
Wave Life Sciences
―
Intellia Therapeutics
―
Stoke Therapeutics
―
Taysha Gene Therapies
―
Ownership Overview
21.71% Insiders
16.05% Mutual Funds
19.34% Other Institutional Investors
32.18% Public Companies and
Individual Investors